TY - JOUR
T1 - Marine v-3 polyunsaturated fatty acid and fish intake after colon cancer diagnosis and survival
T2 - CALGB 89803 (Alliance)
AU - Van Blarigan, Erin L.
AU - Fuchs, Charles S.
AU - Niedzwiecki, Donna
AU - Ye, Xing
AU - Zhang, Sui
AU - Song, Mingyang
AU - Saltz, Leonard B.
AU - Mayer, Robert J.
AU - Mowat, Rex B.
AU - Whittom, Renaud
AU - Hantel, Alexander
AU - Benson, Al
AU - Atienza, Daniel
AU - Messino, Michael
AU - Kindler, Hedy
AU - Venook, Alan
AU - Ogino, Shuji
AU - Giovannucci, Edward L.
AU - Meyerhardt, Jeffrey A.
N1 - Funding Information:
This work was supported by the National Cancer Institutes at the NIH [U10CA180821 and U10CA180882 to the Alliance for Clinical Trials in Oncology, U10CA032291, U10CA041287, U10CA045808, U10CA077651, U10CA138561, U10CA180791, U10CA180820 to ECOG-ACRIN, U10CA180836 (to H.L. Kindler); U10CA180867, U10CA180888 (SWOG), UG1CA189858, P50CA127003, K07CA197077 (to E.L. Van Blarigan); R01CA118553 (to C.S. Fuchs); R01CA149222 (to J.A. Meyerhardt); R35CA197735 (to S. Ogino)]. The work was also supported in part by funds from Pharmacia & Upjohn Company (now Pfizer Oncology).
Publisher Copyright:
© 2018 American Association for Cancer Research.
PY - 2018/4
Y1 - 2018/4
N2 - Background: Marine w-3 polyunsaturated fatty acids (PUFAs), primarily found in dark fish, may prevent colorectal cancer progression, in part through inhibition of prostaglandin-endoperoxide synthase 2 (PTGS2). However, data in humans are limited. Methods: We examined marine w-3 PUFAs and fish intake and survival among 1,011 colon cancer patients enrolled in Cancer and Leukemia Group B 89803 between 1999 and 2001 and followed through 2009. Diet was assessed during and 6 months after chemotherapy. We used Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for disease-free (DFS), recurrence-free (RFS), and overall survival (OS). Results: We observed 343 recurrences and 305 deaths (median follow-up: 7 years). Patients in the highest vs. lowest quartile of marine w-3 PUFA intake had an HR for DFS of 0.72 (95% CI, 0.54–0.97; Ptrend ¼ 0.03). Individuals who consumed dark fish 1/week versus never had longer DFS (HR 0.65; 95% CI, 0.48–0.87; P-value ¼ 0.007), RFS (HR 0.61; 95% CI, 0.46–0.86; Ptrend ¼ 0.007), and OS (HR 0.68; 95% CI, 0.48–0.96; Ptrend ¼ 0.04). In a subset of 510 patients, the association between marine w-3 PUFA intake and DFS appeared stronger in patients with high PTGS2 expression (HR 0.32; 95% CI, 0.11–0.95; Ptrend ¼ 0.01) compared with patients with absent/low PTGS2 expression (HR 0.78; 95% CI, 0.48–1.27; Ptrend ¼ 0.35; Pinteraction ¼ 0.19). Conclusions: Patients with high intake of marine w-3 PUFAs and dark fish after colon cancer diagnosis may have longer DFS.
AB - Background: Marine w-3 polyunsaturated fatty acids (PUFAs), primarily found in dark fish, may prevent colorectal cancer progression, in part through inhibition of prostaglandin-endoperoxide synthase 2 (PTGS2). However, data in humans are limited. Methods: We examined marine w-3 PUFAs and fish intake and survival among 1,011 colon cancer patients enrolled in Cancer and Leukemia Group B 89803 between 1999 and 2001 and followed through 2009. Diet was assessed during and 6 months after chemotherapy. We used Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for disease-free (DFS), recurrence-free (RFS), and overall survival (OS). Results: We observed 343 recurrences and 305 deaths (median follow-up: 7 years). Patients in the highest vs. lowest quartile of marine w-3 PUFA intake had an HR for DFS of 0.72 (95% CI, 0.54–0.97; Ptrend ¼ 0.03). Individuals who consumed dark fish 1/week versus never had longer DFS (HR 0.65; 95% CI, 0.48–0.87; P-value ¼ 0.007), RFS (HR 0.61; 95% CI, 0.46–0.86; Ptrend ¼ 0.007), and OS (HR 0.68; 95% CI, 0.48–0.96; Ptrend ¼ 0.04). In a subset of 510 patients, the association between marine w-3 PUFA intake and DFS appeared stronger in patients with high PTGS2 expression (HR 0.32; 95% CI, 0.11–0.95; Ptrend ¼ 0.01) compared with patients with absent/low PTGS2 expression (HR 0.78; 95% CI, 0.48–1.27; Ptrend ¼ 0.35; Pinteraction ¼ 0.19). Conclusions: Patients with high intake of marine w-3 PUFAs and dark fish after colon cancer diagnosis may have longer DFS.
UR - http://www.scopus.com/inward/record.url?scp=85045520458&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045520458&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-17-0689
DO - 10.1158/1055-9965.EPI-17-0689
M3 - Editorial
C2 - 29358223
AN - SCOPUS:85045520458
SN - 1055-9965
VL - 27
SP - 438
EP - 445
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 4
ER -
